MedTrace Logo

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

NCT06984146 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-11-26

No results posted yet for this study

Summary

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Conditions

  • Hodgkin Lymphoma, Adult

Interventions

DRUG

Nivolumab

40 mg day 1 and 15

DRUG

Doxorubicin

25 mg/m2 day 1 and 15

DRUG

Vinblastine

6 mg/m2 (not exceeding 10 mg) day 1 and 15

DRUG

Dacarbazine

375 mg/m2 day 1 and 15

Sponsors & Collaborators

  • National Medical Research Radiological Centre of the Ministry of Health of Russia

    lead OTHER

Principal Investigators

  • Andrey Kaprin · FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2028-01-31
Completion
2029-01-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06984146 on ClinicalTrials.gov